Van Assche, G., Sandborn, W. J., Feagan, B. G., Salzberg, B. A., Silvers, D., Monroe, P. S., . . . Shames, R. S. (2006). Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: A randomised, double blind, placebo controlled, dose ranging trial. BMJ Group.
Chicago-стиль цитированияVan Assche, G., et al. Daclizumab, a Humanised Monoclonal Antibody to the Interleukin 2 Receptor (CD25), for the Treatment of Moderately to Severely Active Ulcerative Colitis: A Randomised, Double Blind, Placebo Controlled, Dose Ranging Trial. BMJ Group, 2006.
MLA-цитированиеVan Assche, G., et al. Daclizumab, a Humanised Monoclonal Antibody to the Interleukin 2 Receptor (CD25), for the Treatment of Moderately to Severely Active Ulcerative Colitis: A Randomised, Double Blind, Placebo Controlled, Dose Ranging Trial. BMJ Group, 2006.